Rahul Dhanda
Overview
Explore the profile of Rahul Dhanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bean S, Dhanda R, Graham C, Hoffman D, Rodriguez-Lee M, Ionescu A, et al.
J Patient Rep Outcomes
. 2025 Mar;
9(1):31.
PMID: 40069518
Background: This study was designed to evaluate content validity of the Dimensional Anhedonia Rating Scale (DARS), a patient-reported outcome measure, in adults with anhedonia in the context of major depressive...
2.
Farber R, Stull D, Witherspoon B, Evans C, Yonan C, Bron M, et al.
J Patient Rep Outcomes
. 2024 Jan;
8(1):2.
PMID: 38175450
Background: Tardive dyskinesia (TD), a movement disorder in which patients experience abnormal involuntary movements, can have profound negative impacts on physical, cognitive, and psychosocial functioning. The Abnormal Involuntary Movement Scale...
3.
Meyer J, Chepke C, Bera R, Perez-Rodriguez M, Lundt L, Franey E, et al.
Ment Health Clin
. 2023 Dec;
13(5):225-232.
PMID: 38131059
Introduction: Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the...
4.
Ganz M, Chavan A, Dhanda R, Serbin M, Yonan C
J Med Econ
. 2021 Jan;
24(1):103-113.
PMID: 33393412
Aims: To evaluate clinical and economic outcomes associated with valbenazine compared with deutetrabenazine in patients with tardive dyskinesia (TD) using a model that accounts for multiple dimensions of patient health...
5.
Dhanda R, Varghese D, Nadipelli V, Fava M, Joshi N, Solem C, et al.
Patient Prefer Adherence
. 2019 Jul;
13:1037-1050.
PMID: 31308636
Purpose: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this...
6.
Denduluri N, Lyman G, Wang Y, Morrow P, Barron R, Patt D, et al.
Clin Breast Cancer
. 2018 Apr;
18(5):380-386.
PMID: 29622384
Background: The effects of chemotherapy dose intensity on patient outcomes in advanced cancer are not well understood. We studied the association between chemotherapy relative dose intensity (RDI) and overall survival...
7.
Chen C, Ravelo A, Yu E, Dhanda R, Schnadig I
J Neurooncol
. 2015 Mar;
122(3):595-605.
PMID: 25773061
This analysis evaluated the efficacy and safety of bevacizumab as monotherapy and with irinotecan for recurrent glioblastoma in community-based practices. Adult patients with bevacizumab-naive, recurrent glioblastoma initiating second-line treatment (July...
8.
Schnadig I, Hutson T, Chung H, Dhanda R, Halm M, Forsyth M, et al.
Clin Genitourin Cancer
. 2014 Aug;
12(6):413-21.
PMID: 25163396
Background: This retrospective study by McKesson Specialty Health (MSH)/US Oncology Network (USON) evaluates dosing patterns of first-line sunitinib for patients with advanced renal cell carcinoma (aRCC) and its association with...
9.
Chen C, Borker R, Ewing J, Tseng W, Hackshaw M, Saravanan S, et al.
Sarcoma
. 2014 Apr;
2014:145764.
PMID: 24683310
Purpose. To assess epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma (mSTS) patients in USA community oncology practices. Methods. This retrospective, descriptive study used US Oncology's iKnowMed electronic...
10.
Chen C, Dhanda R, Tseng W, Forsyth M, Patt D
J Oncol Pract
. 2013 Aug;
9(4):182-7.
PMID: 23942918
Purpose: Oncotype Dx 21-gene assay recurrence score (RS) predicts recurrence of early-stage breast cancer (ESBC). We investigated whether patient, tumor, or practice characteristics drive its use and explored Oncotype DX...